BDBM118911 US9682940, 166::US9682940, 167::US9682940, 200

SMILES OC(=O)c1ccc(cc1F)S(=O)(=O)N1CCC(CC1)c1n(nc2ccc(cc12)C(c1ccc(Cl)cc1)c1ccc(Cl)cc1)C1CC1

InChI Key InChIKey=GRCCTSKNHXJORL-UHFFFAOYSA-N

Data  6 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 6 hits for monomerid = 118911   

TargetCannabinoid receptor 1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM118911(US9682940, 167 | US9682940, 200 | US9682940, 166)
Affinity DataEC50:  2nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2018
Entry Details
US Patent

TargetCannabinoid receptor 1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM118911(US9682940, 167 | US9682940, 200 | US9682940, 166)
Affinity DataEC50:  12nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2018
Entry Details
US Patent

TargetCannabinoid receptor 1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM118911(US9682940, 167 | US9682940, 200 | US9682940, 166)
Affinity DataEC50:  624nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2018
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM118911(US9682940, 167 | US9682940, 200 | US9682940, 166)
Affinity DataEC50:  2.39E+3nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2018
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM118911(US9682940, 167 | US9682940, 200 | US9682940, 166)
Affinity DataEC50: >1.00E+4nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2018
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM118911(US9682940, 167 | US9682940, 200 | US9682940, 166)
Affinity DataEC50: >1.00E+4nMAssay Description:CB1 and CB2 receptors are Gi-coupled GPCR. Activation of CB1 and CB2 receptors results in a decrease in cAMP production. An inverse agonist of the CB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2018
Entry Details
US Patent